NCT04747470View on ClinicalTrials.gov

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

November 7, 2022

Study Completion Date

November 7, 2022

Conditions

Advanced Solid Tumors

Interventions

DRUG

GS-3583

Administered as an intravenous (IV) infusion

DRUG

Zimberelimab

Administered as an IV infusion

DRUG

Cisplatin

Administered as an IV infusion

DRUG

Carboplatin

Administered as an IV infusion

DRUG

5-Fluorouracil

Administered as an IV infusion

DRUG

Docetaxel

Administered as an IV infusion

Trial Locations (4)

10029

Icahn School of Medicine at Mount Sinai, New York

49546

START Midwest, Grand Rapids

78229

NEXT oncology, San Antonio

97239

Oregon Health & Science University, Portland

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY